Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Diane Potvin

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Clinical Pharmacology in Drug Development|April 29, 2016
Impact of Tesamorelin, a Growth Hormone-Releasing Factor (GRF) Analogue, on the Pharmacokinetics of Simvastatin and Ritonavir in Healthy VolunteersShirley Teng, Diane Potvin, Jean-Claude Mamputu, et al.
The New England Journal of Medicine|December 7, 2007
Metabolic effects of a growth hormone-releasing factor in patients with HIVJulian Falutz, Soraya Allas, Koenraad Blot, et al.
AIDS (London, England)|August 12, 2008
Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulationJulian Falutz, Soraya Allas, Jean-Claude Mamputu, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 27, 2010
Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extensionJulian Falutz, Diane Potvin, Jean-Claude Mamputu, et al.
British Journal of Haematology|April 26, 2017
A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphomaConnie L Batlevi, Michael Crump, Charalambos Andreadis, et al.
Targeted Oncology|March 29, 2022
Phase I Study of Glesatinib (MGCD265) in Combination with Erlotinib or Docetaxel in Patients with Advanced Solid TumorsAmita Patnaik, Shirish Gadgeel, Kyriakos P Papadopoulos, et al.
Plos One|January 11, 2018
AZP-531, an unacylated ghrelin analog, improves food-related behavior in patients with Prader-Willi syndrome: A randomized placebo-controlled trialSoraya Allas, Assumpta Caixàs, Christine Poitou, et al.
Lung Cancer (Amsterdam, Netherlands)|February 28, 2024
Phase II study investigating the efficacy and safety of glesatinib (MGCD265) in patients with advanced NSCLC containing MET activating alterationsDavid S Hong, Federico Cappuzzo, Byoung Chul Cho, et al.
Targeted Oncology|December 2, 2022
Phase I Study Evaluating Glesatinib (MGCD265), An Inhibitor of MET and AXL, in Patients with Non-small Cell Lung Cancer and Other Advanced Solid TumorsChristian Kollmannsberger, Herbert Hurwitz, Lyudmila Bazhenova, et al.
Circulation. Arrhythmia and Electrophysiology|November 28, 2022
First Randomized, Multicenter, Placebo-Controlled Study of Self-Administered Intranasal Etripamil for Acute Conversion of Spontaneous Paroxysmal Supraventricular Tachycardia (NODE-301)Bruce S Stambler, Francis Plat, Philip T Sager, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Clinical Pharmacology in Drug Development|April 29, 2016
Impact of Tesamorelin, a Growth Hormone-Releasing Factor (GRF) Analogue, on the Pharmacokinetics of Simvastatin and Ritonavir in Healthy VolunteersShirley Teng, Diane Potvin, Jean-Claude Mamputu, et al.
The New England Journal of Medicine|December 7, 2007
Metabolic effects of a growth hormone-releasing factor in patients with HIVJulian Falutz, Soraya Allas, Koenraad Blot, et al.
AIDS (London, England)|August 12, 2008
Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulationJulian Falutz, Soraya Allas, Jean-Claude Mamputu, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 27, 2010
Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extensionJulian Falutz, Diane Potvin, Jean-Claude Mamputu, et al.
British Journal of Haematology|April 26, 2017
A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphomaConnie L Batlevi, Michael Crump, Charalambos Andreadis, et al.
Targeted Oncology|March 29, 2022
Phase I Study of Glesatinib (MGCD265) in Combination with Erlotinib or Docetaxel in Patients with Advanced Solid TumorsAmita Patnaik, Shirish Gadgeel, Kyriakos P Papadopoulos, et al.
Plos One|January 11, 2018
AZP-531, an unacylated ghrelin analog, improves food-related behavior in patients with Prader-Willi syndrome: A randomized placebo-controlled trialSoraya Allas, Assumpta Caixàs, Christine Poitou, et al.
Lung Cancer (Amsterdam, Netherlands)|February 28, 2024
Phase II study investigating the efficacy and safety of glesatinib (MGCD265) in patients with advanced NSCLC containing MET activating alterationsDavid S Hong, Federico Cappuzzo, Byoung Chul Cho, et al.
Targeted Oncology|December 2, 2022
Phase I Study Evaluating Glesatinib (MGCD265), An Inhibitor of MET and AXL, in Patients with Non-small Cell Lung Cancer and Other Advanced Solid TumorsChristian Kollmannsberger, Herbert Hurwitz, Lyudmila Bazhenova, et al.
Circulation. Arrhythmia and Electrophysiology|November 28, 2022
First Randomized, Multicenter, Placebo-Controlled Study of Self-Administered Intranasal Etripamil for Acute Conversion of Spontaneous Paroxysmal Supraventricular Tachycardia (NODE-301)Bruce S Stambler, Francis Plat, Philip T Sager, et al.
Pageof 3